Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdreView H/M Ratio Comparison with LFOV vs SFOV-HE SPECT
NCT01868841Phase 4Completed
- Start
- Dec 2013
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Iobenguane in heart failure (HF) and cardiomyopathy (2 arms). Primary endpoint: Relationship of H/M ratios obtained on LFOV and SFOV-HE systems at 3 months. Started Dec 2013; status: completed.
02
Drugs
Iobenguane
03
Conditions
heart failure (HF)cardiomyopathy
Beyond the preview
Go deeper on NCT01868841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01868841.